Nonmyeloablative Allogeneic Stem Cell Transplantation Using Alternative Donors

Weiden P.L. , Flournoy N. , Thomas E.D. Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts. N Engl J Med. 1979; 300: 1068–1073.

Sullivan K.M. , Weiden P.L. , Storb R. Influence of acute and chronic graft-versus-host disease on relapse and survival after bone marrow transplantation from HLA-identical siblings as treatment of acute and chronic leukemia. Blood. 1989; 73: 1720–1728.

Horowitz M.M. , Gale R.P. , Sondel P.M. Graft-versus-leukemia reactions after bone marrow transplantation. Blood. 1990; 75: 555–562.

Dadmarz R. , Sgagias M.K. , Rosenberg S.A. CD4+ T lymphocytes infiltrating human breast cancer recognise autologous tumor in an MHC-class II restricted fashion. Cancer Immunol Immunother. 1995; 40: 1–9.

Rocha M. , Umansky V. , Lee K.H. Differences between graft-versus-leukemia and graft-versus-host reactivity. I. Interaction of donor immune T cells with tumor and/or host cells. Blood. 1997; 89: 2189–2202.

Klingemann H.G. , Storb R. , Fefer A. Bone marrow transplantation in patients aged 45 years and older. Blood. 1986; 67: 770–776.

Storb R. , Epstein R.B. , Rudolph R.H. Allogeneic canine bone marrow transplantation following cyclophosphamide. Transplantation. 1969; 7: 378–386.

Storb R. , Weiden P.L. , Graham T.C. Hemopoietic grafts between DLA-identical canine littermates following dimethyl myleran: evidence for resistance to grafts not associated with DLA and abrogated by antithymocyte serum. Transplantation. 1977; 24: 349–357.

Kawai T. , Cosimi A.B. , Colvin R.B. Mixed allogeneic chimerism and renal allograft tolerance in cynomolgus monkeys. Transplantation. 1995; 59: 256–262.

Kimikawa M. , Sachs D.H. , Colvin R.B. Modifications of the conditioning regimen for achieving mixed chimerism and donor-specific tolerance in cynomolgus monkeys. Transplantation. 1997; 64: 709–716.

Watanabe K. , Ito I. , Otani F. Factors influencing long-term operational tolerance in dogs treated with fractionated lymphoid irradiation, donor bone marrow cell infusion and FK506. Transplant Proc. 1995; 27: 221–224.

Storb R. , Raff R.F. , Appelbaum F.R. Comparison of fractionated to single-dose total body irradiation in conditioning canine littermates for DLA-identical marrow grafts. Blood. 1989; 74: 1139–1143.

Yu C. , Storb R. , Mathey B. DLA-identical bone marrow grafts after low-dose total body irradiation: effects of high-dose corticosteroids and cyclosporine on engraftment. Blood. 1995; 86: 4376–4381.

Stewart F.M. , Zhong S. , Wuu J. Lymphohematopoietic engraftment in minimally myeloablated hosts. Blood. 1998; 91: 3681–3687.

Slavin S. , Nagler A. , Naperstek . Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood. 1998; 91: 756.

Giralt S. , Estey E. , Albitar M. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. Blood. 1997; 89: 4531–4536.

Khouri I.F. , Keating M. , Korbling M. Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. J Clin Oncol. 1998; 16: 2817–2824.

Kottaridis P.D. , Milligan D.W. , Chopra R. In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation. Blood. 2000; 96: 2419–2425.

Mohty M. , Bay J.O. , Faucher C. Graft-versus-host disease following allogeneic transplantation from HLA-identical sibling with antithymocyte globulin-based reduced intensity preparative regimen. Blood. 2003; 102: 470–476.

Morris E.C. , Rebello P. , Thomson K.J. Pharmacokinetics of alemtuzumab used for in vivo and in vitro T-cell depletion in allogeneic transplantations: relevance for early adoptive immunotherapy and infectious complications. Blood. 2003; 102: 404–406.

Koh L.P. , Rizzieri D.A. , Long G.D. Campath-1H, T cell depleted nonmyeloablative peripheral blood stem cell transplantation from 3-6/6 HLA matched family members. Blood. 2002; 100: 2512. Abstract.

Giralt S. , Thall P.F. , Khouri I. Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation. Blood. 2001; 97: 631–637.

Nagler A. , Aker M. , Or R. Low-intensity conditioning is sufficient to ensure engraftment in matched unrelated bone marrow transplantation. Exp Hematol. 2001; 29: 362–370.

Niederwieser D. , Maris M. , Shizuru J.A. Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induce durable complete chimerism and sustained remissions in patients with hematological diseases. Blood. 2003; 15: 101: 1620–1629.

Maris M.B. , Niederwieser D. , Sandmaier B.M. HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with hematologic malignancies. Blood. 2003; 102: 2021–2030.

Wong R. , Giralt S.A. , Martin T. Reduced-intensity conditioning for unrelated donor hematopoietic stem cell transplantation as treatment of myeloid malignancies in patients older than 55 years. Blood. 2003; 102: 3052–3059.

Beatty P.G. , Dahlberg S. , Mickelson E.M. Probability of finding HLA-matched unrelated marrow donors. Transplantation. 1988; 45: 714–718.

Kernan N.A. , Bartsch G. , Ash R.C. Analysis of 462 transplantations from unrelated donors facilitated by the National Marrow Donor Program. N Engl J Med. 1993; 328: 593–602.

Marks D.I. , Cullis J.O. , Ward K.N. Allogeneic bone marrow transplantation for chronic myeloid leukemia using sibling and volunteer unrelated donors: a comparison of complications in the first 2 years. Ann Intern Med. 1993; 119: 207–214.

McGlave P. , Bartsch G. , Anasetti C. Unrelated donor marrow transplantation therapy for chronic myelogenous leukemia: initial experience of the National Marrow Donor Program. Blood. 1993; 81: 543–550.

Hansen J.A. , Gooley T.A. , Martin P.J. Bone marrow transplants from unrelated donors for patients with chronic myeloid leukemia. N Engl J Med. 1998; 338: 962–968.

Morton A.J. , Gooley T. , Hansen J.A. Association between pretransplant interferon-alpha and outcome after unrelated donor marrow transplantation for chronic myelogenous leukemia in chronic phase. Blood. 1988; 92: 394–401.

Marks D.I. , Cullis J.O. , Ward K.N. Allogeneic bone marrow transplantation for chronic myeloid leukemia using sibling and volunteer unrelated donors: a comparison of complications in the first 2 years. Ann Intern Med. 1993; 119: 207–214.

Bornhauser M. , Thiede C. , Platzbecker U. Dose-reduced conditioning and allogeneic hematopoietic stem cell transplantation from unrelated donors in 42 patients. Clin Cancer Res. 2001; 7: 2254–2262.

Kusumi E. , Hamaki T. , Kami M. Feasibility of reduced-intensity bone marrow transplantation (RIST) from a matched unrelated donors. Blood. 2002; 100: 5452. Abstract.

Bashey A. , Wiita K. , Garrett J. Unrelated donor hematopoietic cell transplantation in older patients using a non-myeloablative preparative regimen: universal donor cell engraftment and reduced regimen-related toxicity. Blood. 2002; 100: 5453. Abstract.

Hongeng S. , Pakakasama S. , Chuansumrit A. Favorable outcome of pilot study of matched unrelated donor bone marrow transplantation in thalassemia patients. Blood. 2002; 100: 5454. Abstract.

Champlin R. T-cell depletion to prevent graft-versus-host disease after bone marrow transplantation. Hematol Oncol Clin North Am. 1990; 4: 687–698.

Aversa F. , Tabilio A. , Velardi A. Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype. N Engl J Med. 1998; 339: 1186–1193.

Reisner Y. , Itzicovitch L. , Meshorer A. Hemopoietic stem cell transplantation using mouse bone marrow and spleen cells fractionated by lectins. Proc Natl Acad Sci U S A. 1978; 75: 2933–2936.

Chao N.J. , Schmidt G.M. , Niland J.C. Cyclosporine, methotrexate, and prednisone compared with cyclosporine and prednisone for prophylaxis of acute graft-versus-host disease. N Engl J Med. 1993; 329: 1225–1230.

Martin P.J. , Hansen J.A. , Torok-Storb B. Graft failure in patients receiving T cell-depleted HLA-identical allogeneic marrow transplants. Bone Marrow Transplant. 1988; 3: 445–456.

Filipovich A.H. , Vallera D.A. , Youle R.J. Graft-versus-host disease prevention in allogeneic bone marrow transplantation from histocompatible siblings: a pilot study using immunotoxins for T cell depletion of donor bone marrow. Transplantation. 1987; 44: 62–69.

Bordignon C. , Keever C.A. , Small T.N. Graft failure after T-cell-depleted human leukocyte antigen identical marrow transplants for leukemia: II. In vitro analyses of host effector mechanisms. Blood. 1989; 74: 2237–2243.

Hale G. , Waldmann H. Control of graft-versus-host disease and graft rejection by T cell depletion of donor and recipient with Campath-1 antibodies: results of matched sibling transplants for malignant diseases. Bone Marrow Transplant. 1994; 13: 597–611.

Ash R.C. , Horowitz M.M. , Gale R.P. Bone marrow transplantation from related donors other than HLA-identical siblings: effect of T cell depletion. Bone Marrow Transplant. 1991; 7: 443–452.

Boehmer H. , Sprent J. , Nabholz M. Tolerance to histocompatibility determinants in tetraparental bone marrow chimeras. J Exp Med. 1975; 141: 322–334.

Symeonidis A. , Bishara A. , Aker M. Allogeneic stem cell transplantation (SCT) from HLA matched family donors other than siblings. Blood. 2000; 96: 5301. Abstract.

Chakraverty R. , Peggs K. , Chopra R. Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using nonmyeloablative conditioning regimen. Blood. 2002; 99: 1071–1078.

Sykes M. , Preffer F. , McAfee S. Mixed lymphohaemopoietic chimerism and graft-versus-lymphoma effects after non-myeloablative therapy and HLA-mismatched bone marrow transplantation. Lancet. 1999; 353: 1755–1759.

Kasow K.A. , Woodard P. , Benaim E. Engraftment of a T cell depleted matched unrelated donor stem cell graft using non-myeloablative condition. Blood. 2000; 96: 5316. Abstract.

Beatty P.G. , Clift R.A. , Mickelson E.M. Marrow transplantation from related donors other than HLA-identical siblings. N Engl J Med. 1985; 313: 765–771.

Anasetti C. , Amos D. , Beatty P.G. Effect of HLA compatibility on engraftment of bone marrow transplants in patients with leukemia or lymphoma. N Engl J Med. 1989; 320: 197–204.

Kernan N.A. , Flomenberg N. , Dupont B. Graft rejection in recipients of T-cell-depleted HLA-nonidentical marrow transplants for leukemia: identification of host derived antidonor allocytotoxic T lymphocytes. Transplantation. 1987; 43: 842–847.

Soiffer R.J. , Mauch P. , Tarbell N.J. Total lymphoid irradiation to prevent graft rejection in recipients of HLA nonidentical T cell-depleted allogeneic marrow. Bone Marrow Transplant. 1991; 7: 23–33.

Rowe J.M. , Lazarus H.M. Genetically haploidentical stem cell transplantation for acute leukemia. Bone Marrow Transplant. 2001; 27: 669–676.

Petersdorf E.W. , Gooley T. , Anasetti C. Optimizing outcome after unrelated marrow transplantation by comprehensive matching of HLA class I and II alleles in the donor and recipient. Blood. 1998; 92: 3515–3520.

Sasazuki T. , Juji T. , Morishima Y. Effect of matching of class I HLA alleles on clinical outcome after transplantation of hematopoietic stem cells from an unrelated donor. N Engl J Med. 1998; 339: 1177–1185.

Handgretinger R. , Schumm M. , Lang P. Transplantation of megadoses of purified haploidentical stem cells. Ann N Y Acad Sci. 1999; 872: 351–362.

Reisner Y. , Martelli M.F. Tolerance induction by “megadose” transplants of CD34+ stem cells: a new option for leukemia patients without an HLA-matched donor. Curr Opin Immunol. 2000; 12: 536–541.

Aversa F. , Tabilio A. , Velardi A. Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype. N Engl J Med. 1998; 339: 1186–1193.

Schwinger W. , Urban C. , Lackner H. Unrelated peripheral blood stem cell transplantation with “megadoses” of purified CD34+ cells in three children with refractory severe aplastic anemia. Bone Marrow Transplant. 2000; 25: 513–517.

Wagner J.E. , Rosenthal J. , Sweetman R. Successful transplantation of HLA-matched and HLA-mismatched umbilical cord blood from unrelated donors: analysis of engraftment and acute graft-versus-host disease. Blood. 1996; 88: 795–802.

Rachamim N. , Gan J. , Segall H. Tolerance induction by “megadose” hematopoietic transplants: donor-type human CD34 stem cells induce potent specific reduction of host anti-donor cytotoxic T lymphocyte precursors in mixed lymphocyte culture. Transplantation. 1998; 65: 1386–1393.

Martin P.J. , Hansen J.A. , Buckner C.D. Effects of in vitro depletion of T cells in HLA-identical allogeneic marrow grafts. Blood. 1985; 66: 664–672.

van Dicke K.A. , Hooft J.I. , van Bekkum D.W. The selective elimination of immunologically competent cells from bone marrow and lymphatic cell mixtures. II. Mouse spleen cell fractionation on a discontinuous albumin gradient. Transplantation. 1968; 6: 562–570.

Rodt H. , Kolb H.J. , Netzel B. Effect of anti-T-cell globulin on graft GVHD in leukemic patients treated with BMT. Transplant Proc. 1981; 13: 257–261.

Prentice H.G. , Blacklock H.A. , Janossy G. Depletion of T lymphocytes in donor marrow prevents significant graft-versus-host disease in matched allogeneic leukaemic marrow transplant recipients. Lancet. 1984; 472–476.

Mitsuyasu R.T. , Champlin R.E. , Gale R.P. Treatment of donor bone marrow with monoclonal anti-T-cell antibody and complement for the prevention of graft-versus-host disease: a prospective, randomized, double-blind trial. Ann Intern Med. 1986; 105: 20–26.

Youle R.J. , Neville D.M. Jr . Anti-Thy 1.2 monoclonal antibody linked to ricin is a potent cell-type-specific toxin. Proc Natl Acad Sci U S A. 1980; 77: 5483.

Martin P.J. , Hansen J.A. , Torok-Storb B. Effects of treating marrow with a CD3 specific immunotoxin for prevention of acute graft-versus-host disease. Bone Marrow Transplant. 1988; 3: 437–444.

Antin J.H. , Bierer B.E. , Smith B.R. Selective depletion of bone marrow T lymphocytes with anti-CD5 monoclonal antibodies: effective prophylaxis for graft-versus-host disease in patients with hematologic malignancies. Blood. 1991; 78: 2139–2149.

O'Reilly R.J. , Collins N.H. , Kernan N. Transplantation of marrow depleted T cells by soybean lectin agglutination and e-rosette depletion: major histocompatibility complex related graft resistance in leukemic transplant recipients. Transplant Proc. 1985; 17: 455.

Fischer A. , Durandy A. , de Villartay J.P. HLA-haploidentical bone marrow transplantation for severe combined immunodeficiency using e rosette fractionation and cyclosporine. Blood. 1986; 67: 444–449.

Reisner Y. , Kapoor N. , Kirkpatrick D. Transplantation for severe combined immunodeficiency with HLA-A, B, D, DR incompatibility parental marrow cells fractionated by soybean agglutinin and sheep red blood cells. Blood. 1983; 61: 341–348.

de Witte T. , Raymakers R. , Plas A. Bone marrow repopulation capacity after transplantation of lymphocyte-depleted allogeneic bone marrow using counterflow centrifugation. Transplantation. 1984; 37: 151–155.

Wagner J.E. , Santos G.W. , Noga S.J. bone marrow graft engineering by counterflow centrifugal elutriation: results of a phase I-II clinical trial. Blood. 1990; 75: 1370–1377.

Patterson J. , Prentice H.G. , Brenner M.K. Graft rejection following HLA matched T-lymphocyte depleted bone marrow transplantation. Br J Haematol. 1986; 63: 221–230.

Kurtzberg J. , Laughlin M. , Graham M.L. Placental blood as a source of hematopoietic stem cells for transplantation into unrelated recipients. N Engl J Med. 1996; 335: 157–166.

Rubinstein P. , Carrier C. , Scaradavou A. Outcome among 562 recipients of placental-blood transplants from unrelated donors. N Engl J Med. 1998; 339: 1565–1577.

Rocha V. , Wagner J.E. Jr , Sobocinski K.A. Graft-versus-host disease in children who have received a cord-blood or bone marrow transplant from an HLA-identical sibling: Eurocord and International Bone Marrow Transplant Registry Working Committee on Alternative Donor and Stem Cell Sources. N Engl J Med. 2000; 342: 1846–1854.

Long G. , Madan J. , Kurtzberg J. Unrelated umbilical cord blood transplants in adult patients with hematologic malignancies or genetic disorders. Blood. 1999; 94(suppl 1): 2544. Abstract.

Barker N.J. , DeFor T. , Verfaille C.M. Transplantation of mismatched unrelated donor umbilical cord blood in adult patients with high risk disease: outcome in recipients of 1-2 × 10⁷ nucleated cells/kilogram. Blood. 1999; 94(suppl 1): 2562. Abstract.

Rocha V. , Arcese W. , Sanz G. Prognostic factors of outcome after unrelated cord blood transplant in adults with hematologic malignancies: Eurocord and International Bone Marrow Transplant Registry Working Committee on Alternative Donor and Stem Cell Sources. Blood. 2000; 96: 2521. Abstract.

Kurtzberg J. , Martin P.L. , Szabolcs P.M. Outcomes of unrelated cord blood transplantation in 158 pediatric patients consecutively transplanted at a single institution using cord blood units from a single bank. Blood. 2000; 96: 878. Abstract.

Barker J.N. , Wagner J.E. Umbilical cord blood transplantation: current state of the art. Curr Opin Oncol. 2002; 14: 160–164.

Rizzieri D.A. , Long G.D. , Vredenburgh J.J. Successful allogeneic engraftment of mismatched unrelated cord blood following nonmyeloablative conditioning. Blood. 2001; 98: 3486–3488.

Rizzieri D.A. , Long G.D. , Vredenburgh J.J. Durable engraftment of mismatched unrelated cord blood following a non-myeloablative preparative regimen for adults. Blood. 2001; 98: 777. Abstract.

McSweeney P.A. , Bearman S.I. , Jones R.B. Nonmyeloablative hematopoietic cell transplants using cord blood. Blood. 2001; 98: 2794. Abstract.

Hwang W.Y.K. , Tan P. , Goh Y.T. Minimal toxicity of an immunosuppression-based nonmyeloablative conditioning regimen for mismatched unrelated umbilical cord blood transplantation. Blood. 2002; 100: 5437. Abstract.

Cairo M.S. , Harrison L. , Del Toro G. Reduced intensity (RI) umbilical cord blood (UCB) and matched family donor (MFD) allogeneic stem cell transplantation (AlloSCT) in children and adolescents with malignant and nonmalignant disease. Blood. 2002; 100: 5432. Abstract.

Shen B.J. , Hou H.S. , Zhang H.Q. Unrelated, HLA-mismatched multiple human umbilical cord blood transfusion in four cases with advanced solid tumors: initial studies. Blood Cells. 1994; 20: 285–292.

Barker J.N. , Weisdorf D.J. , DeFor T.E. Rapid and complete donor chimerism in adult recipients of unrelated donor umbilical cord blood transplantation after reduced-intensity conditioning. Blood. 2003; 102: 1915–1919.

Wang C. , Wan L. , Yan S. Different sources of hematopoietic cells for allogeneic transplantation in severe aplastic anemia. Blood. 2002; 100: 5391. Abstract.

Klein A.K. , Patel D.D. , Gooding M.E. T-cell recovery in adults and children following umbilical cord blood transplantation. Biol Blood Marrow Transplant. 2001; 7: 454–466.

Mackall C.L. , Fleisher T.A. , Brown M.R. Age, thymopoiesis, and CD4+ T-lymphocyte regeneration after intensive chemotherapy. N Engl J Med. 1995; 332: 143–149.

Parkman R. Antigen-specific immune function after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2003; 9: 287–291.

Triffet A. , Lewalle P. , Delforge A. Adult haplo-identical transplants: hazards and benefits of DLI and of the type of post-transplant growth factor (G-CSF vs GM-CSF). Blood. 2002; 100: 5429. Abstract.

Mitterbauer M. , Kalhs P. , Keil F. Molecular and clinical remission after dose-reduced and myeloablative allogeneic and syngeneic stem cell transplantation in patients with advanced non-Hodgkin's lymphoma: a comparative single center study. Blood. 2002; 100: 1647. Abstract.

Khouri I.F. , Ming-Sheng L. , Saliba R.M. Nonablative allogeneic stem cell transplantation for relapsed mantle cell lymphoma (MCL): a promising strategy for an aggressive disease. Blood. 2002; 100: 1652. Abstract.

Blum W. , Girgis M. , Hallemeier C. Outcomes for patients with non-Hodgkin's lymphoma following donor transplantation using low dose, single exposure total body irradiation and cyclophosphamide conditioning: a single institution experience. Blood. 2002; 100: 1653. Abstract.

Corradini P. , Dodero A. , Zallio F. Nonmyeloablative conditioning followed by allogeneic transplantation has a better outcome than high-dose chemotherapy plus autografting in non Hodgkin lymphoma with T-cell histology. Blood. 2002; 100: 1654. Abstract.

Velardi A. , Ruggeri L. , Moretta A. NK cells: a lesson from mismatched hematopoietic transplantation: response from Velardi et al. Trends Immunol. 2002; 23: 438–444.